Yahoo won't let me post - go to investorvillage (dotcom) to ACAD board post number 129 for entire report. Its worth the read - excellent detail in this initiation report
If you only recently got involved with this company the answers to your questions are in this report
Good report. As a PharmD one thing I can add is that it will be tried off-label for everything you can imagine. Anyone know if it can be formulated as an injectable? May have emergent/ICU uses (ie continuous infusion) without usual side effects
Sentiment: Strong Buy
What can it hurt ? Your not going to know less by reading it
The report is good and thorough, but disappointing in terms of timeframe and revenue in my opinion. Makes me wonder about a lower price target and longer time to get there.
Pretty detailed report...just gives you more time to stock up...time will tell
Very good, Thanks.